According to FutureWise analysis the market for cell free fetal DNA testing in 2023 is US$ 1.46 billion, and is expected to reach US$ 3.39 billion by 2031 at a CAGR of 11.1%.
Cell-free fetal DNA testing is a safe and non-invasive extension of prenatal testing. Prenatal tests are conducted to detect any irregularities in a fetus. Traditionally, prenatal tests include chorionic villus sampling (CVS) and amniocentesis, both of which are invasive and can harm the developing fetus, resulting in miscarriage in some cases. Cell-free fetal DNA is a new alternative to prenatal tests. During pregnancy, fetal DNA is found in the mother's bloodstream. Cell-free fetal DNA enters the bloodstream through the placenta, a flattened organ in the uterus where maternal blood and fetal blood flow. Fetal DNA can be identified by its unique sequence. Fragmented into very acute segments, less than 200 base pairs on average. Blood also contains maternal DNA fragments. After 22-25 days of fertilization, fetal DNA is first detected, and its concentration increases as the pregnancy progresses. The seventh week of pregnancy is the time when fetal DNA can be used to diagnose pregnancy. Fetal DNA is rarely distinguished from maternal DNA through diagnostic testing. It is possible to perform amniocentesis and chorionic villus sampling prenatal tests within 14-20 weeks and 10-13 weeks of pregnancy, respectively. The cell-free fetal DNA non-invasive test is used to detect aneuploidy syndromes, fetal Down syndrome and signals a major shift in diagnostic practice.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Cell Free Fetal DNA Testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Cell Free Fetal DNA Testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.